Navigation Links
Canandian Firm Announces Positive Results from Anti- Cervical Cancer Drug Trials

The Helix BioPharma Corporation has announced positive results from its phase II clinical study of its Topical Interferon Alpha-2b in women with human papilloma virus (HPV)-induced low-grade cervical lesions.//

Human papilloma viruses (HPVs) are a large group of related viruses. They play a part in the development of cervical epithelial cancers. HPV is also associated with skin, oral and anal cancers.

Helix BioPharma Corporation is a Canada-based firm specializing in cancer therapies.

It says that its study showed a clinically efficacious response to the topical interferon treatment in nearly half of the treated patients. In addition, the product demonstrated an excellent safety profile, with no significant adverse side-effects.

Prof. Dr. Achim Schneider, a renowned expert in the field of cervical cancer and Director of the Department of Gynaecology at the Charité University Hospital in Berlin, said, . "Helix's product shows real promise as a practical and effective pharmaceutical means of preventing cervical cancer development in women affected by HPV-induced cervical lesions."

Twenty women received Topical Interferon Alpha-2b, self-administered intravaginally three times per week for a period of 6 weeks with a follow-up evaluation at 12 weeks, compared with 21 separately studied women who received no treatment whatsoever over the same study period.

Nearly half (46.7%) of the women in the treated population had their abnormal Pap smears revert to normal during the 12 week period, compared with only 15.8% of the untreated women (i.e., nearly a three-fold improvement).

In a PAP test cells from the cervix are collected for examination under a microscope. It is used to detect changes that may be cancer or may lead to cancer. It is named after George Papanicolaou, an American anatomist. "We are very pleased to have achieved this milestone in the continuing development of our Topical Inte rferon Alpha-2b product candidate," said John Docherty, Helix's Vice President of Corporate Development.

"Helix is committed to further advancing its clinical development program for this extremely prevalent condition, in order to bring this product to market as expeditiously as possible."

Interferon alpha-2b is an immune system modulator that is active against variety of HPV-induced lesions. Immune modulation is a new emerging field in the medical treatment of viral infections. It works by introducing an agent into the body that boosts specific areas of the immune system.

Interferon alpha-2b is thought to function by triggering an antiviral response within infected cells and by mobilizing the body's natural immune system to destroy the infected cells.

Helix's Topical Interferon Alpha-2b is expected to offer a safe, discreet, self-administered and pain-free therapy.
GP
'"/>




Related medicine news :

1. Ramdoss Announces Introduction of RCH-II
2. Britain Announces Third Transfusion Related Mad Cow Case
3. Tibet Announces the Dalai Lama’s Tour of South Americ
4. Indian PM Announces Of Setting Up India Study Center At Tashkent
5. PowderMed Announces Needle-Less Flu Vaccine
6. Malaysia Announces Prison term On People Donating HIV-Contaminated Blood
7. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
8. Australian Government Announces Survey To Tackle Childhood Obesity
9. New Zealand Announces 10-year Plan For Betterment Of Mental Health Care
10. Apollo Announces Research on Indian Cardiac Epidemic
11. Government Announces Steps To Promote Ayurvedic Medicine
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/8/2016)... ... 2016 , ... David J. Dykeman , Ginger Pigott , and ... speak at DeviceTalks West, Dec. 12, 2016, at the Fairmont Newport Beach in California. ... firm’s global Life Sciences & Medical Technology Group have been featured speakers at every ...
(Date:12/8/2016)... Tampa, Fla (PRWEB) , ... December 08, 2016 ... ... offering smarter modes of access for customers and employees that are both engaging ... ChangeGear 7 with Service Smart Technology, the software company revealed today its plans ...
(Date:12/8/2016)... ... 2016 , ... Catalent Pharma Solutions, the leading global provider ... products, today announced that it had joined the Pharmaceutical Supply Chain Initiative (PSCI). ... unite pharmaceutical and healthcare companies that share a vision of better, social, environmental ...
(Date:12/8/2016)... ... December 08, 2016 , ... STAT courier is pleased ... a convenient service for Texas, they are expanding their presence in Dallas. One of ... spree that will bring new jobs to the Dallas and Forth Worth market. STAT ...
(Date:12/8/2016)... ... December 08, 2016 , ... Today’s patients are encouraged to ... mind, SIGVARIS has created a new line of anti-embolism stockings to help prevent ... the benefits of graduated compression when transitioning from recovery to early rehabilitation. , ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... AMSTERDAM , December 8, 2016 Information ... TM metrics in Scopus , the world,s largest ... free access to comprehensive metrics for journals from over 5,000 publishers. ... publish, which journals to subscribe to and when to adjust a ... , , ...
(Date:12/8/2016)... 2016 According to the research report, ... is expected to be worth US$9.7 bn by the ... Between the forecast years of 2016 and 2024, the global ... The leading players operating in the global diabetes injection pens ... plc., Biocon Ltd., and Sanofi S.A. Transparency Market Research reports ...
(Date:12/8/2016)... 2016 According to a new market research report ... Therapeutic (Pain, Insulin)), End Use (Sports, Fitness, RPM), Type (Smart watch, Patch), ... global market, in terms of value, is projected to reach 12.14 Billion ... 18.0% during the forecast period. Continue Reading ... ...
Breaking Medicine Technology: